Categories AlphaGraphs, Earnings, Health Care
Infographic: Highlights of Merck’s (MRK) Q3 2022 earnings
Merck & Co., Inc. (NYSE: MRK) reported a modest increase in adjusted earnings for the third quarter of 2022 when the pharmaceutical company’s net sales grew by 14%.
Worldwide sales rose 14% year-over-year to $14.9 billion during the quarter. Pharmaceutical sales grew 13%, which was partially offset by a 3% sales drop in the animal health segment.
Third-quarter earnings, on an adjusted basis, moved up to $1.85 per share from $1.78 per share in the same quarter of 2021. Unadjusted net income was $3.25 billion or $1.28 per share in the most recent quarter, compared to $4.57 billion or $1.80 per share in the corresponding period of the previous year.
Check this space to read management/analysts’ comments on Merck’s Q3 2022 earnings report
“Our third quarter results demonstrate exceptional revenue and underlying earnings growth and sustained performance across our key growth drivers. Inspired by our purpose of saving and improving lives around the world, I am confident we are well-positioned to continue to deliver strong operational performance,” said Robert Davis, chief executive officer of Merck.
Stocks you may like:
Key takeaways from Cintas’ (CTAS) third-quarter 2023 report
Cintas Corporation (NASDAQ: CTAS) has been growing its market share by diversifying into new areas and through acquisitions. The prudent business model, with a focus on recurring revenues, has helped
Here are a few points to keep in mind if you are considering Starbucks Corporation (SBUX)
Shares of Starbucks Corporation (NASDAQ: SBUX) stayed in green on Thursday. The stock has gained 10% over the past 12 months. The company delivered healthy results for its most recent
ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9%
AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter when the medical device maker's revenues increased by 9%. The company also provided guidance for fiscal